Vitamin D deficiency does not alter biochemical markers of bone metabolism before or after autograft in patients with multiple myeloma

European Journal of Haematology

Volumn 85, Issue 1, 2010, Pages 65-67

  Laroche, Michel ^a   Lemaire, Olivia ^a   Attal, Michel ^a  

^a CHU PURPAN   (France)

Author keywords

Bone mineral density; Bone remodelling; Multiple myeloma; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; MELPHALAN; PARATHYROID HORMONE; TELOPEPTIDE;

ADULT; ARTICLE; AUTOGRAFT; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE DENSITY; BONE METABOLISM; BONE REMODELING; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS LINKING; DISEASE MARKER; DRUG MEGADOSE; FEMALE; HUMAN; LUMBAR SPINE; MALE; MULTIPLE MYELOMA; PARATHYROID HORMONE BLOOD LEVEL; PREVALENCE; PRIORITY JOURNAL; VITAMIN D DEFICIENCY;

ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; CALCIFEDIOL; CALCIUM; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; PROCOLLAGEN; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; VITAMIN D DEFICIENCY;

EID: 77953823347     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01436.x     Document Type: Article

References (9)

1. Souberbielle JC, Friedlander G, Kahan A, Cormier C. Evaluating vitamin D status, implications for preventing and managing osteoporosis and other chronic diseases. Joint Bone Spine 2006 73 : 249 253.
2. Badros A, Goloubeva O, Terpos E, Milliron T, Baer MR, Streeten E. Prevalence and significance of vitamin D deficiency in multiple myeloma patients. Br J Haematol 2008 142 : 492 494.
3. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996 335 : 91 97.
4. Mariette X, Bergot C, Ravaud P, Roux C, Laval-Jeantet M, Brouet JC, Fernand JP. Evolution of bone densitometry in patients with myeloma treated with conventional or intensive therapy. Cancer 1995 76 : 1559 1563.
5. Bischoff-Ferrari HA, Giovannucci E, Willet WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006 84 : 18 28.
6. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int 2005 16 : 713 716.
7. Roodman GD. Myeloma bone disease: pathogenesis and treatment. Oncology 2005 19 : 983 984.
8. Holick MF. Vitamin D deficiency. N Engl J Med 2007 357 : 266 281.
9. Puthier D, Bataille R, Barillé S, Mellerin MP, Harousseau JL, Ponzio A, Robillard N, Widjenes J, Amiot M. Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone. Blood 1996 88 : 4659 4666.